CSE AIML | OTCQB AIMLF | FWB 42FB
PRESS RELEASE

AI/ML Innovations Inc. Welcomes Industry Trailblazers to Board of Directors

January 9, 2025

· Mark Orsmond, a Pioneering Force in Canadian Healthcare, Appointed Executive Chair

· Michael Nemirow Joins as Director, Bringing Decades of Entrepreneurial Expertise

Vancouver, Canada – AI/ML Innovations Inc. (“AIML” or the “Company”) (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) is pleased to announce the appointment of two distinguished leaders to its Board of Directors. Mark Orsmond, a highly respected pioneer among healthcare executives in Canada, joins as Executive Chair, while seasoned business entrepreneur Michael Nemirow steps into the role of Director.

Mark Orsmond has earned a reputation as a transformative leader in Canadian healthcare, with a career spanning over 30 years. Often credited with shaping the landscape of healthcare business in Canada, he has successfully founded and scaled multiple ventures, including three healthcare businesses that were sold to Well Health Technologies Corp. (TSX: WELL). His extensive experience includes serving as CFO and Executive Vice President at the Corix Group of Companies and the ALL-SEA Group of Companies. A holder of a B.Compt degree from the University of South Africa and a CPA designation, Mr. Orsmond’s leadership has consistently driven organizational success and premier exits.

Michael Nemirow brings an entrepreneurial acumen honed over decades of scaling and transforming businesses across diverse industries. As CEO of Greenstar Plant Products, Inc., Mr. Nemirow led a strategic overhaul, streamlining operations, acquiring a complementary organic brand, and driving the company’s global presence in markets such as North America, South America, Europe, and Australia. Under his leadership, Greenstar grew into a globally recognized manufacturer and was acquired by a public U.S. company in 2021.

“We are privileged to welcome two exceptional leaders to our Board,” said Paul Duffy, CEO of AIML. “Mark Orsmond’s unparalleled influence in Canadian healthcare and Michael Nemirow’s entrepreneurial expertise will be invaluable as AIML accelerates its global expansion and innovation in health technology. Their strategic guidance will be a cornerstone of our future success.”

The Company also extends its gratitude to Tim Daniels for his leadership as Executive Chairman. Mr. Daniels will remain a valued member of the Board.

Stock Options Grant

The Company further announces the grant of stock options to a director to purchase up to 250,000 common shares of the Company (“Shares”) at an exercise price of $XXX per Share for a term of five years. The options will vest quarterly over one year.

For more information about AIML:

For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.

For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com.

About AI/ML Innovations Inc. https://aiml-innovations.com/

AIML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through its acquisition of Quantum Sciences Ltd. (100% owned by AIML),  NeuralCloud Solutions Inc. (100% owned by AIML), and strategic partnerships with Health Gauge Inc. (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 11.11% currently owned by AIML), AI Rx Inc. (70% owned by AIML), and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AIML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

On behalf of the Board of Directors
Tim Daniels, Director

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Read More

April 22, 2025
AIML Innovations Appoints Jared Adelstein to Board of Directors
Read More
April 15, 2025
AIML Announces Closing of Oversubscribed Private Placement
Read More
April 7, 2025
AIML Updates Terms of Proposed Private Placement Announced
Read More
April 4, 2025
AIML Announces Proposed Private Placement
Read More
January 9, 2025
AI/ML Innovations Inc. Welcomes Industry Trailblazers to Board of Directors
Read More
January 23, 2025
AI/ML Innovations Inc. Appoints Dr. Alan Rabinowitz as Chief Medical Officer and Director of Medical Partnerships
Read More
January 28, 2025
Andrea Ruth Joins AI/ML Innovations as Head of Quality, Clinical, and Regulatory Affairs
Read More
February 20, 2025
Key Updates to Upcoming Annual and Special Meeting
Read More
March 14, 2025
AIML Aligns Leadership for Growth and Shareholder Value Creation
Read More
March 21, 2025
AIML Continues to Streamline for the Future and Moves Beyond Tech2Heal
Read More